Crystalys’s dotinurad is currently in pivotal testing for gout, a prevalent inflammatory disorder with few treatment options. The drug has the same mechanism of action as a molecule that Sobi added to its pipeline through a $950 million acquisition.
Candid's Series D round was led by Sixth Street Growth, with participation from Oak HC/FT, 8VC and Y Combinator.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
VBC aligns reimbursements to outcomes, emphasizing the quality and effectiveness, not quantity, of healthcare activities. But the same cost constraints driving interest in VBC can also turn it into a liability.
A core principle of trauma-informed care is understanding that past and ongoing exposure to stress and trauma can directly shape health outcomes. But by remaining blind to these histories, the medical community severely limits its ability to address the very drivers of the diseases it is trying to cure.
Drug spending continues to grow, but that doesn’t mean that everyone is getting the medicines that they need. A panel at MedCity News’ Bullseye event discussed the evolution of the prescription drug marketplace.
Health tech investors say the founders who win them over aren't the ones with all the answers, but the ones who know exactly what they don't know — and build a team to cover the gap.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
Priority Health partnered with Color Health and Grail to offer self-funded employers virtual cancer navigation, support and multi-cancer early detection beginning in 2027.
We’re about to enter a world beyond just talking to a chat tool about your health. AI tools are on the precipice of being able to take action on their advice.
The question is no longer whether healthcare innovation is accelerating. The question is where investors gain access to generate the strongest returns.
Scribe Therapeutics’ IPO will support a pipeline led by a genetic medicine that represses expression of its target gene without making permanent changes. Common chronic cardiometabolic conditions are Scribe’s initial focus as the biotech works to bring genetic medicines beyond rare diseases.
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
Unlike past healthcare tech waves sold on cost savings, AI is proving it can generate new revenue — with returns as high as 100x, according to a panel of investors at MedCity News' Bullseye event.
SCAN Health Plan CEO Sachin Jain and Ascendiun CEO Paul Markovich argued that healthcare leaders share responsibility for the industry's shortcomings and called for greater accountability and systemic reform.
Hospitals that see improved long-term results in behavioral health patients will be those that prioritize metrics aligned with their care pathways.
Groundbreaking new therapies have exciting potential to treat and cure diseases while minimizing burden on patients; however, they create major clinical, operational and financial implications that must be planned for years in advance.
Assured Health raised $19 million for its AI agents that verify provider credentials and manage insurance enrollment for health systems and group practices. The startup said it can cut a process that usually takes months down to days.